

NHG DSRB Ref: 2018/00045

01 February 2018

Dr Yip Cherng Hann, Benjamin
Department of General Medicine
Khoo Teck Puat Hospital

Dear Dr Yip

NHG DOMAIN SPECIFIC REVIEW BOARD (DSRB) APPROVAL

STUDY TITLE: Treatment modalities and outcomes in patients with non-variceal upper bleeding gastrointestinal tract (NVUBGIT)

We are pleased to inform you that the NHG Domain Specific Review Board has approved the application as titled above to be conducted in **Khoo Teck Puat Hospital**.

The approval period is from **01 February 2018 to 31 January 2019**. The NHG DSRB reference number for this study is **2018/00045**. Please use this reference number for all future correspondence.

The documents reviewed are:

- a) NHG DSRB Application Form: **Version No. 1**
- b) Data Collection Form: **Version 1 dated 23 February 2017**

The NHG DSRB has approved your request for waiver of informed consent.

Continued approval is conditional upon your compliance with the following requirements:

1. No deviation from or changes to the study should be implemented without documented approval from the NHG DSRB, except where necessary to eliminate apparent immediate hazard(s) to the study subjects.
2. Any deviation from or changes to the study to eliminate an immediate hazard should be promptly reported to the NHG DSRB within seven calendar days.
3. Please note that for studies requiring CTA/CTN/CTC, apart from the approval from NHG DSRB, no deviation from, or changes of the Research Protocol and Informed Consent Form should be implemented without documented approval from the Health Sciences Authority unless otherwise advised by the Health Sciences Authority.
4. Please submit the following to the NHG DSRB:
 - a. All Unanticipated Problems Involving Risk To Subjects Or Others (UPIRTSOs) must be reported to

the NHG DSRB. For more than minimal risk studies, all problems involving local deaths must be reported as soon as possible, but not later than **7 calendar days** after first knowledge by the Investigator, regardless of the causality and expectedness of the death event, and any additional relevant information about the death should be reported within **8 calendar days** of making the initial report. For no more than minimal risk studies, only problems involving local deaths that are related or possibly related to the study must be reported as soon as possible, but not later than **7 calendar days** after first knowledge by the Investigator, and any additional relevant information about the death should be reported within **8 calendar days** of making the initial report. For problems which are life threatening, it should be reported as soon as possible, but not later than **7 calendar days** after first knowledge by the investigator, and any additional relevant information about the problems should be reported within **8 calendar days** of making the initial report. All other problems that fulfil the UPIRTSOs reporting criteria must be reported as soon as possible but not later than **15 calendar days** after first knowledge by the Investigator.

- b. Report(s) on any new information that may adversely affect the safety of the subject or the conduct of the study.
- c. NHG DSRB Study Status Report Form – this is to be submitted 4 to 6 weeks prior to expiry of the approval period. The study cannot continue beyond **31 January 2019** until approval is renewed by the NHG DSRB.
- d. Study completion – this is to be submitted using the NHG DSRB Study Status Report Form within 4 to 6 weeks of study completion.

Established since May 2006, the NHG Research Quality Management (RQM) Program seeks to promote the responsible conduct of research in a research culture with high ethical standards, identify potential systemic weaknesses and make recommendations for continual improvement. Hence, this research study may be randomly selected for a review by the Research Quality Management (RQM) team. For more information, please visit www.research.nhg.com.sg.

The NHG DSRB operates in accordance to the ICH GCP and all applicable laws and regulations.

Yours Sincerely

Dr Madelynn Chan
Chairperson
NHG Domain Specific Review Board E

Cc: Institutional Representative, KTPH
c/o Clinical Research Unit, KTPH
Departmental Representative of General Medicine, KTPH

(This is an electronic-generated letter. No signature is required.)